Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

Markets & Finance

CS First Boston Cuts Merck to Hold from Buy


Shares of Merck & Co. (MRK) fell after CS First Boston downgraded the drug company to hold from buy. During intraday trading on Tuesday, Merck forecasted 2002 EPS growth to be at same level as in 2001.

Analyst Ken Kulju notes Merck significantly lowered EPS guidance (the second time in six months), largely tied to continuing signs of gross margin erosion in its core pharmaceuticals business. Kulju notes the loss of patent protection on Prilosec, Prinivil, and adverse Merck-Medco revenue mix effects are expected to drive gross margin down an additional 2% in 2002 to about 37%.

He adds this adjustment largely is responsible for the sharp $0.39 drop in his 2002 EPS forecast to $3.07. The analyst also cut his $3.81 2003 EPS estimate to $3.43, and his $80 stock price target to $67.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus